Gavin Macbeath News Today

USA News Group Commentary VANCOUVER, BC, May 28, 2024 /PRNewswire/ -- USA News Group - Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults

Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial developmentWALTHAM, Mass., April 08, 2024 -- TScan Therapeutics, Inc. , a clinical-stage...

TScan’s abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of initial data from a large prospective clinical trial assessing...

Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies

WALTHAM, Mass., Dec. 04, 2023 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment...

WALTHAM, Mass., Nov. 30, 2023 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment...

Shares of TScan Therapeutics, Inc. (TCRX) are up 5% on Tuesday after the company announced that it received FDA clearance for its IND application for TSC-203-A0201, a TCR-T targeting PReferentially expressed Antigen in Melanoma (PRAME).

TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapyWALTHAM, Mass., Aug. 29, 2023 -- TScan...

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ... | June 16, 2023

TSC-200-A0201 is TScan’s third cleared IND for the T-Plex solid tumor program supporting the use of multiple TCRs in combination to deliver customized, multiplexed TCR-T cell therapies based on... | June 6, 2023